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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYHuman pluripotent stem cells (hPSCs) represent a renewable source of pancreatic beta cells for both basic research and therapeutic appli-
cations. Given this outstanding potential, significant efforts have been made to identify the signaling pathways that regulate pancreatic
development in hPSC differentiation cultures. In this study, we demonstrate that the combination of epidermal growth factor (EGF) and
nicotinamide signaling induces the generation of NKX6-1+ progenitors from all hPSC lines tested. Furthermore, we show that the size of
theNKX6-1+ population is regulated by the duration of treatmentwith retinoic acid, fibroblast growth factor 10 (FGF10), and inhibitors of
bonemorphogenetic protein (BMP) andhedgehog signaling pathways.When transplanted intoNOD scid gamma (NSG) recipients, these
progenitors differentiate to give rise to exocrine and endocrine cells, includingmonohormonal insulin+ cells. Together, these findings pro-
vide an efficient and reproducible strategy for generating highly enriched populations of hPSC-derived beta cell progenitors for studies
aimedat further characterizing theirdevelopmental potential invivoanddeciphering thepathways that regulate theirmaturation invitro.INTRODUCTION
To generate functional beta cells from human pluripotent
stem cells (hPSCs), it is necessary to accurately model the
key stages of pancreatic development in the differentiation
cultures used. Studies in the mouse have shown that the
exocrine, endocrine, and ductal lineages of the adult
pancreas derive from multipotent progenitor cells (MPCs)
that are specified between embryonic day 9.5 (E9.5) and
E12.5 of development and are characterized by the co-
expression of a combination of transcription factors,
including Pdx1, Ptf1a,Nkx6-1,Cpa,Myc, and Sox9 (Burlison
et al., 2008; Gu et al., 2002; Haumaitre et al., 2005; Hense-
leit et al., 2005; Kawaguchi et al., 2002; Kopp et al., 2011;
Seymour and Sander, 2007; Solar et al., 2009; Zhou et al.,
2007). Development of the ductal/endocrine lineages
from MPCs is associated with loss of Ptf1a and mainte-
nance of Nkx6-1 expression, whereas the downregulation
of Nkx6-1 and sustained expression of Ptf1a are required
for specification of the exocrine lineage (Schaffer et al.,
2010). Expression of Nkx6-1 is required for development
of the beta cell lineage from endocrine progenitors (Sander
et al., 2000).
The generation of MPCs in the mouse fetus is preceded
by the emergence of an independent population of insu-
lin-expressing cells that is distinguished from the adult
beta cell population by the fact that the cells are polyhor-Stemmonal and non-glucose responsive, and do not express
Nkx6-1 (Jørgensen et al., 2007; Teitelman et al., 1993). Line-
age-tracing studies have shown that these polyhormonal
cells do not give rise to adult beta cells, leading to the hy-
pothesis that they represent an embryonic/fetal lineage
that is distinct from MPCs (Herrera, 2000; Herrera et al.,
1994). The observation that deletion of Nkx6-1 inhibits
the development of adult beta cells, but not polyhormonal
cells (Sander et al., 2000), further supports the interpreta-
tion that these two populations of endocrine cells arise
from separate lineages that are established through
different developmental programs. The program that gives
rise to polyhormonal cells is known as the first transition,
whereas the one that generates the MPCs and adult endo-
crine cells is referred to as the second transition. Immuno-
histochemical analyses of human fetal pancreata suggest
that endocrine specification differs somewhat between hu-
mans and mice, as the first cells to be detected in humans
are monohormonal insulin+ cells (Jennings et al., 2013).
Polyhormonal cells have been observed in the human
pancreas between gestational week 9 (G9w) and G16w;
however, they appear to arise after the formation of mono-
hormonal cells (Jennings et al., 2013; Pan and Brissova,
2014). These findings suggest that if two distinct programs
exist in humans, commitment to the monohormonal line-
age (the human equivalent of the second-transition popu-
lation) would occur faster in humans than in mice.Cell Reports j Vol. 4 j 591–604 j April 14, 2015 j ª2015 The Authors 591
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A number of different studies over the past decade have
demonstrated that it is possible to generate pancreatic cells,
including both polyhormonal and monohormonal insu-
lin-expressing cells from hPSCs (Nostro and Keller, 2012;
Pagliuca et al., 2014; Rezania et al., 2014). Polyhormonal
cells display characteristics of the murine first-transition
endocrine population, as they are NKX6-1 and non-
glucose responsive. They likely represent the polyhormo-
nal population found in the human fetal pancreas after
G9w. Monohormonal insulin+ cells express NKX6-1, are
glucose responsive, and are comparable to the second-tran-
sition-derived endocrine cells in mice and the monohor-
monal cells detected in humans as early as G7.5w (Jennings
et al., 2013; Pan and Brissova, 2014).
As the presence of NKX6-1 is one of the distinguishing
features of these two lineages, expression of this transcrip-
tion factor is used to monitor the emergence of the beta
cell lineage in hPSC differentiation cultures. Populations
enriched in NKX6-1+ cells will give rise to functional beta
cells following transplantation into immunodeficient
mice, indicating that they do indeed represent progenitors
of adult monohormonal lineages (Kelly et al., 2011; Kroon
et al., 2008). Currently, the signalingpathways that regulate
the generation of the NKX6-1+ progenitors are not well
defined. hPSC-line heterogeneity appears to be one factor
that can influence the generation of the beta cell progeni-
tors, as Kelly et al. (2011) reported the development of pop-
ulations consistingof 6%–45%NKX6-1+ cells fromdifferent
cell lines with the same protocol. More recently, Rezania
et al. (2012) showed that activation of PKC can enhance
the generation of theNKX6-1+ progenitors, whereas inhibi-
tion of the transforming growth factor b (TGF-b) pathway
blocks their development in H1 and ESI49 differentiation
cultures. The effect of PKC activation, however, has not
been tested on a broad range of hPSC lines.
In this report, we show that the combination of
epidermal growth factor (EGF) and nicotinamide signaling
together with inhibition of the bone morphogenetic pro-
tein (BMP) pathways promotes the efficient development
of NKX6-1+ progenitors from all of the hPSC lines tested.Figure 1. NOGGIN, EGF, and Nicotinamide Induce NKX6-1 Express
(A) Schematic of the protocol used to differentiate hESCs toward pan
treated with NOGGIN, EGF, and nicotinamide, singly or in combinatio
(B) Flow-cytometric analysis for GFP was carried out at d13 of differe
(C) Average percentage of NKX6-1:GFP+ cells as measured by flow-cyt
groups (, untreated; N, NOGGIN; E, EGF; NA, nicotinamide; NE, NO
tinamide). Error bars represent SD of the mean (n = 3 independent e
(D) Kinetic analysis of NKX6-1:GFP expression as measured by flow cyto
from the mean of three experiments. **p < 0.05, ***p < 0.001 using
(E) qPCR analysis for NKX6-1, PDX1, PTF1A, and SOX9 expression durin
NKX6-1GFP/w cells were differentiated as described in (A). Expression
with adult pancreas (AP, dashed bar). Error bars represent SD of the
See also Figures S1 and S2.
StemAdditionally, we demonstrate that the duration of retinoic
acid/fibroblast growth factor 10 (RA/FGF10) induction and
inhibition of BMP and hedgehog signaling influences
endocrine lineage development, with a short duration fa-
voring the specification of NKX6-1+ progenitors, and an
extended duration promoting the development of poly-
hormonal cells. Following transplantation into NOD scid
gamma (NSG) recipient mice, the NKX6-1+ progenitors
induced with NOGGIN, EGF, and nicotinamide (NENA)
mature and give rise to the different endocrine lineages,
including beta-like cells.RESULTS
EGF and Nicotinamide Signaling Induces the
Development of NKX6-1+ Progenitors
Our current differentiation protocol optimized for the gen-
eration of the pancreatic lineages (Nostro et al., 2011) sup-
ports the development of low numbers of NKX6-1+ cells
along with polyhormonal insulin-expressing cells from
both H1 and INSGFP/w human embryonic stem cells
(hESCs). However, these cell types emerge as distinct popu-
lations in cultures (Figures S1A and S1B), consistent with
the interpretation that they represent separate lineages.
Based on the observations that EGF signaling is required
for branching morphogenesis during endocrine lineage
development, and that both EGF-family ligands and recep-
tors are widely expressed in the mouse and human fetal
pancreas (Gittes, 2009; Miettinen et al., 1995; Miettinen
and Heikinheimo, 1992; Miettinen et al., 2000), we specu-
lated that this pathway could be instrumental in the gener-
ation of hESC-derived NKX6-1-expressing pancreatic
progenitors. To test this hypothesis, we generated hESC-
derived pancreatic endoderm using a modified version of
our previously described protocol (Nostro et al., 2011)
and then cultured the cells for an additional 10 days with
different combinations of EGF, NOGGIN, and nicotin-
amide to specify the NKX6-1 progenitor fate (Figure 1A).
We then analyzed the populations for the presence ofion
creatic endoderm. At the final stage of differentiation, cells were
ns.
ntiation.
ometry analysis at d13 of differentiation in the different treatment
GGIN+EGF; NNA, NOGGIN+nicotinamide; NENA, NOGGIN+EGF+nico-
xperiments).
metry between d7 and d17 of differentiation. Error bars represent SD
Student’s t test for statistical analysis.
g pancreatic differentiation of the NKX6-1GFP/w hESC line (d7–d17).
levels are normalized to the housekeeping gene TBP and compared
mean (n = 3 independent experiments).
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NKX6-1+ cells. NOGGIN was included because several
studies have demonstrated that BMP signaling is dispens-
able for normal pancreatic development (Bardeesy et al.,
2006; Wandzioch and Zaret, 2009), and nicotinamide was
tested because it has been shown to promote endocrine dif-
ferentiation from human fetal explants (Otonkoski et al.,
1993). To be able to monitor NKX6-1 expression quantita-
tively, we used an hESC reporter line in which the GFP
cDNA had been targeted to the NKX6-1 locus (A.H.,
A.G.E., and E.G.S., unpublished data).
NOGGIN, EGF, or nicotinamide alone did not promote
the development of a significant number of NKX6-1:GFP+
cells (Figures 1B and 1C). In contrast, the combinations of
EGF and nicotinamide or EGF, nicotinamide, andNOGGIN
induced the generation of sizable populations of NKX6-1:
GFP+ cells, representing more than 40% and 70% of the to-
tal culture, respectively (Figures 1Band1C). Kinetic analysis
of the population induced withNENA showed that the first
NKX6-1:GFP+ cells were detected by day 10 (d10) of differ-
entiation and the size of the population increased rapidly
to peak at d13 (Figure 1D). To validate the fidelity of the
NKX6-1GFP/whESC reporter line, we performed intracellular
flow-cytometric analyses on NKX6-1:GFP-derived d13 cells
using an anti-NKX6-1 antibody. As shown in Figures S1C–
S1E, the antibody stained the majority of the GFP+ popula-
tion, indicating thatGFP expression is indicative ofNKX6.1
expression. To further characterize the NENA-induced pop-
ulation, we analyzed it for the expression of markers indic-
ative ofMPCs, including PDX1, PTF1a, SOX9, andNKX6-1.
The kinetics of NKX6-1 mRNA expression correlated
well with that of NKX6-1:GFP, further confirming that
GFP reflects endogenous NKX6-1 activity (Figures 1D and
1E). PTF1a, SOX9, and PDX1 (Figure 1E) were all expressed
during the d7–d17 time frame in temporal patterns
that overlapped with that of NKX6-1. Together, these
findings strongly suggest that the combination of EGF
and nicotinamide signaling together with inhibition of
the BMP pathway promotes the efficient development of
progenitors that display expression patterns indicative
of MPCs.
To investigate whether this approach for generating
NKX6-1+ cells is broadly applicable to other hPSCs, we
tested combinations of EGF, NOGGIN, and nicotinamide
on H1 and H9 hESC lines, and analyzed the development
of NKX6-1+ cells by intracellular flow cytometry. Similar
to our observations with the NKX6-1GFP/w line, the addi-
tion of NOGGIN, EGF, or nicotinamide alone had little ef-
fect, whereas the combination of all three pathway regula-
tors induced populations consisting of up to 60%NKX6-1+
cells (Figure 2A). Titration experiments revealed that the
proportion of NKX6-1+ cells increased with increasing con-
centrations of EGF, up to a maximum of 80% following in-
duction with 100 or 300 ng/ml of the factor (Figure S2A).594 Stem Cell Reports j Vol. 4 j 591–604 j April 14, 2015 j ª2015 The AuthoAdditionally, they established optimal concentrations of
NOGGIN between 10 and 100 ng/ml and of nicotinamide
at 10 mM (Figures S2B and S2C).
The NENA-induced, H1-derived population also ex-
pressed the spectrum of transcription factors indicative of
MPCdevelopment, including PDX1, PTF1a, and SOX9 (Fig-
ure 2B). The temporal pattern of expression of these tran-
scription factors was similar to that observed with the
NKX6-1GFP/w-derived population and overlapped with
that of NKX6-1 (Figures 1E and 2B). Some of the hESC-
derived pancreatic cells appeared to be undergoing
commitment to the endocrine lineages, as expression of
the endocrine-specific transcription factors NEUROD1
and NGN3 was also upregulated during this time frame
(Figure 2B). To further characterize the NENA-induced pop-
ulations, we analyzed them for the presence of theNKX6-1,
PDX1, and SOX9 proteins by immunofluorescence. The
differentiated culture contained cells that co-expressed
NKX6-1 and PDX1, and NKX6-1 and SOX9 (Figure 2C),
consistent with the interpretation that they represent
MPCs or endocrine/ductal progenitors.
Given that Rezania et al. (2012) showed that activation
of PKC enhanced the generation of NKX6-1+ progenitors,
we were interested in determining whether direct manipu-
lation of the PKC pathway would impact the development
of this population in the presence of NENA. Interestingly,
we did not observe any increase in the percentage of
NKX6-1+ cells at d13 of differentiation following addition
of the PKC activator TPB (Figure S2D). In contrast, inhibi-
tion of PKC with the specific inhibitor Go¨6976 (Chen
et al., 2009) led to a modest but significant reduction in
the percentage of NKX6-1+ cells, suggesting that PKC
signaling plays some role in the development of NKX6-1+
progenitors, and that the pathway was already active in
our NENA-induced population (Figure S2D). Induction of
stage 4 H1-derived cells with TPB and NOGGIN in the
absence of EGF and nicotinamide promoted the develop-
ment of a small NKX6-1+ population (10%). The size of
this population was not influenced by the addition of
SB431542 (SB) or nicotinamide (Figure S2E). An alternative
PKC activator, PdBu (Rezania et al., 2012), was more effec-
tive than TPB, as addition of it together with NOGGIN in
the absence of EGF and nicotinamide resulted in the gener-
ation of a population consisting of 30% NKX6-1+ cells
(Figure S2F). Higher concentrations of PdBU did not lead
to an increase in the size of the NKX6-1+ population
(Figure S2F).
The Duration of Stage 3 Impacts the Development of
the NKX6.1 Progenitors and the Polyhormonal
Population
Because stage 3 is essential for establishing the pancreatic
fate in differentiation cultures, we were interested inrs
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Figure 2. NOGGIN, EGF and Nicotinamide Induce NKX6-1 Expression in Non-Targeted hESC Lines
(A) Flow-cytometric analysis of intracellular NKX6-1. H1 cells and H9 hESCs were differentiated according to a published protocol (Nostro
et al., 2011) up to stage 3 and then treated with NOGGIN, EGF and nicotinamide, alone or in combination, for 6 days. Flow-cytometric
analysis was performed at d13 of differentiation. Triple treatment was sufficient to induce the highest percentage of NKX6-1+ cells. Error
bars represent SD of the mean (n = 3 independent experiments). ***p < 0.001 using Student’s t test.
(B) qPCR analysis for NKX6-1, PDX1, PTF1A, SOX9, NEUROD1, and NGN3 expression between d7 and d17 of pancreatic differentiation.
Expression levels are normalized to the housekeeping gene TBP and compared with adult pancreas (AP, dashed bar). Error bars represent SD
of the mean (n = 5 independent experiments).
(C) Immunofluorescence image of d13 culture, showing NKX6-1 in green and PDX1 and SOX9 in red. The solid bar is 200 mm.
See also Figures S1 and S2.determining whether the duration of this induction step
could influence the type of progenitors that develop.
Additionally, we investigated the role of TGF-b signalingStemduring the NENA step because Rezania et al. (2012) pro-
vided evidence that it is required for the generation of
the NKX6.1+ progenitors, whereas we previously showedCell Reports j Vol. 4 j 591–604 j April 14, 2015 j ª2015 The Authors 595
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Figure 3. Short RA/Cyclopamine/FGF10 Exposure and Activin Treatment Favor NKX6-1 Development
(A) Schematic of the protocol used to differentiate hPSCs toward first- and/or second-transition progenitors. Stage 3 of differentiation
consisted of NOGGIN, cyclopamine, RA, and FGF10 (NCRF). Sant-1 was used as a substitute for cyclopamine and purmorphamine (2.5, 7.5,
and 22.5 mM) was used to activate hedgehog signaling in the absence of Sant-1 and cyclopamine.
(B–E) NCRF treatment lasted for 1–4 days. Stage 4 of differentiation was supplemented with SB431542 (SB) or activin A at 0.3, 1, 3, and
9 ng/ml (A 0.3, A 1, A 3, and A 9). Average percentage of NKX6-1:GFP+ cells in red (B and D) and C-peptide+ in black (C and E) as measured
by flow-cytometry analysis at d11, d12, d13, and d14 of differentiation. Error bars represent SD of the mean of the percentage of C-peptide+
(legend continued on next page)
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that it is not necessary for specification of the polyhor-
monal population (Nostro et al., 2011). For these ana-
lyses, we used H1 hESCs and the iPSC line 38-2. Day 6
cells were induced for 1, 2, 3, or 4 days with a combina-
tion of NOGGIN, cyclopamine, RA, and FGF10 (NCRF;
stage 3 media) and then cultured for 4 days in NENA in
the presence of either the TGF-b inhibitor SB or different
concentrations of activin A (0–9 ng/ml; Figure 3A). The
percentage of NKX6-1+ and C-peptide+ cells was evalu-
ated at d11, d12, d13 and d14 of differentiation, respec-
tively (Figures 3B–3E and S3). With this staining strategy,
C-peptide+NKX6-1 cells are considered as polyhormonal
cells equivalent to the murine first-transition population,
whereas C-peptideNKX6-1+ cells represent putative MPC
progenitors (equivalent to the murine second-transition
progenitors). Double-positive C-peptide+NKX6-1+ cells
were not detected under any of the tested conditions (Fig-
ure S3A). Several interesting patterns emerged from these
experiments. First, the duration of the stage 3 induction
step dramatically influenced the development of the pol-
yhormonal population, as significantly more C-pepti-
de+NKX6-1 cells were detected in both H1- and 38-2-
derived populations induced for 4 days than in those
induced for 1 or 2 days (Figures 3C, 3E, and S3A). In
contrast, 1 or 2 days of induction was optimal for devel-
opment of the NKX6-1+ population from both hPSC
lines, as extended stage 3 induction resulted in a decrease
in the proportion of NKX6-1+ cells that developed
in vitro (Figures 3B, 3D, and S3A). Second, activin treat-
ment modestly increased the proportion of NKX6-1+ cells
generated from H1 and 38-2 cells. Given these findings, it
is possible that the size of the NKX6-1+ progenitor popu-
lation could be increased with higher concentrations of
activin A in these hPSC lines (Figures 3B and 3D). Third,
addition of the TGF-b inhibitor led to a small but signif-
icant reduction in the proportion of NKX6-1+ cells that
developed in the H1-derived population, whereas it
completely inhibited the emergence of NKX6-1+ cells in
the 38-2-derived population (Figures 3B, 3D, and S3A).
TGF-b signaling did not have any impact on the differen-
tiation of another hESC line, MEL1, which gave rise to
60% NKX6-1+ cells when differentiated for 2 days in
stage 3 media (Figure S3B). A reduction in the duration
of stage 3 from 2 days to 1 day led to a consistent in-
crease in the percentage of NKX6-1+ cells generatedand NKX6-1+ cells (n = 5 independent experiments, except for C-peptid
t test.
(F and G) The NRF treatment lasted 2 or 4 days and hedgehog signalin
22.5 mM) or inhibited by treatment with Sant-1 (2.5 mM). Average perc
measured by flow-cytometry analysis at d12 and d14 of differentiatio
Error bars represent SD of the mean of the percentage of C-peptide+ a
one-way ANOVA and Student’s t test for comparisons between d12-d1
Stemfrom two additional hiPSC lines, MSC-iPSC1 and
BJ-iPSC1 (Figure S3C).
Studies inmouse and chick embryos have shown that in-
hibition of hedgehog signaling creates a permissive envi-
ronment for pancreatic specification (Apelqvist et al.,
1997; Hebrok et al., 1998, 2000). To test whether the
hedgehog signaling pathway plays a role in the develop-
ment of human NKX6-1+ cells, we treated differentiating
cultures with NOG, FGF10, and RA alone or in combina-
tion with either Sant-1 or cyclopamine (data not shown)
to block the hedgehog signaling pathway, or with
increasing concentrations of purmorphamine, a hedgehog
pathway agonist (Sinha and Chen, 2006). We treated H1-
derived cells with these molecules for 2 or 4 days and
then with NENA for an additional 4 days, and then evalu-
ated the NKX6-1 and C-peptide profiles by flow cytometry
at d12 and d14, respectively. Interestingly, the percentage
of NKX6-1+ cells that were generated at d12 of differentia-
tion from the progenitors treated for 2 days with the stage
3 factors was not affected by activation or inhibition of the
hedgehog pathway (Figure 3F). In contrast, the size of the
d14 NKX6-1+ population that developed from the progen-
itors treated for 4 days with the stage 3 factors was
impacted by manipulation of the hedgehog pathway. Spe-
cifically, activation of the pathway with purmorphamine
(at 7.5 and 22.5 mM) led to an increase in the percentage
of NKX6-1+ cells (Figure 3F). The reverse pattern was
observed for the C-peptide+NKX6-1 population. The
highest frequency of C-peptide+NKX6-1 cells was gener-
ated from progenitors treated for 4 days with the hedgehog
inhibitor together with the stage 3 factors. Addition of pur-
morphamine during the 4-day period significantly reduced
the proportion of these cells (Figure 3G).
Taken together, these findings clearly indicate that the
duration of the stage 3 induction step influences the ratio
of polyhormonal cells and NKX6.1+ progenitors that
develop within the culture, and demonstrate that a short
induction period, independent of hedgehog signaling, pro-
motes the development of populations that consist pre-
dominantly of NKX6-1+ expressing cells. They also show
that prolonged culture with NOG, FGF10, and RA together
with inhibition of hedgehog signaling is required for the
formation of polyhormonal cells. Finally, they suggest
that the requirement for TGF-b signaling for NKX6-1 in-
duction is cell-line specific.e 38-2: n = 3 independent experiments). **p < 0.01 using Student’s
g was activated during this stage by purmorphamine (2.5, 7.5, and
entage of NKX6-1:GFP+ cells in red (F) and C-peptide+ in black (G) as
n.
nd NKX6-1+ cells (n = 4 independent experiments); *p < 0.05 using
4 NSRF treatments. See also Figure S3.
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Table 1. Efficiency of Differentiation
Cell Line
Stage 4 Percentage
of NKX6-1+ Cells ±
Average Deviation
Stage 1
Duration
of Stage 3
Stage 4
(EGF) ng/ml
Stage 4
(Act A) ng/ml
Percentage of
CXCR4+/CD117+
H1 83.1 ± 4.2 >93% 2 days 100 –
H9 56.4 ± 2 >93% 3 days 50 –
NKX6-1GFP/w 71.0 ± 3.2 >93% 2 days 100 –
MEL-1 67.5 ± 11.5 >93% 2 days 50 3
INSGFP/w 82.6 ± 8.8 >93% 2 days 100 –
hiPSCs 38-2 36.9 ± 6.4 >93% 1 day 50 9
MSC-iPSC1 83.8 ± 2.1 >93% 1 day 100 –
BJ-iPSC1 74.6 ± 10.5 >93% 1 day 100 –
Replicates: n = 3 independent experiments for H9, NKX6-1GFP/w, MEL1, MSC-iPSC1, BJ-iPSC1; n = 4 independent experiments for H1, INSGFP/w; n = 5 inde-
pendent experiments for hiPSC 38-2.The efficiencies of differentiation, including endoderm
induction and NKX6-1 progenitor specification across the
different hPSC lines, are summarized in Table 1.NENA-Induced Progenitors Generate Islet-like
Structures In Vivo
To determine whether the NENA-induced population con-
tains endocrine progenitors, we transplanted cells from
d13 H1-derived cultures into the mammary fat pad of
immunocompromised NSG mice as previously described
(Basford et al., 2012). The grafts were harvested at 1.5, 3,
5, and 6 months post-transplantation and analyzed for
the expression of NKX6-1, cytokeratin-19 (CK19), insulin
(INS), C-peptide, glucagon (GCG), somatostatin (SST),
and pancreatic polypeptide (PP). At the 1.5-month time
point, we detected high numbers of NKX6-1+ cells and cells
that expressed CK19 (Figure S4A). Low numbers of INS+,
C-peptide+, and GCG+ cells were also detected at this
time point. Almost all of these INS+ cells were NKX6-1+
and none co-expressed C-peptide and GCG, indicating
that they represent monohormonal endocrine cells (Fig-
ure S4A). Interestingly, the INS+ cells were also CK19 but
were located in close proximity to CK19+ cells (Figure S4A).
Between 3 and 6 months post-transplantation, we
observed islet-like structures within the grafts (Figure 4
and data not shown) that contained NKX6-1+, INS+,
GCG+, SST+, and PP+ monohormonal cells. Trypsin+ and
CK19+ cells were also detected at this time point, suggest-
ing that acinar and ductal lineage cells were present in
the graft. Interestingly, at this time point, fewer endocrine
cells were found within the CK19+ structures.
To determine whether the site of transplantation
impacted differentiation, we transplanted a comparable598 Stem Cell Reports j Vol. 4 j 591–604 j April 14, 2015 j ª2015 The AuthoH1-derived progenitor population under the kidney cap-
sules of NSG mice. We observed a similar pattern of devel-
opment within the grafts, as they contained monohormo-
nal endocrine cells and TRYP+ cells (Figure S4B). Glucose
challenge tests were performed at 6, 12, and 18 weeks
post-transplantation. Significantly higher levels of human
C-peptide were detected after glucose challenge in the sera
of the transplanted mice at 18 weeks in four out of five ex-
periments (Figure S5). The average percentage of NKX6-1+
cells transplanted per experiment was 64% ± 2.4% (range:
60.5%–70%). Each transplantation was successful, and we
did not observe any correlation between the level of C-pep-
tide in the sera and the percentage of transplanted
NKX6-1+ cells (data not shown). These findings are in
agreement with previous reports (Kroon et al., 2008; Reza-
nia et al., 2011). Overall, these data indicate that NENA
treatment generates a population that contains progenitors
that can give rise to beta-like cells in vivo.DISCUSSION
The efficient generation of functional cell types from
hPSCs in vitro is dependent on precise manipulation of
the appropriate signaling pathways at key developmental
stages within the lineage of interest. Efforts to identify
the pathways that regulate pancreatic development
in vitro are complicated by the existence of two develop-
mental programs that give rise to distinct endocrine cell
types. Our findings in this study uncover important differ-
ences in the regulation of the two programs and show that
NKX6-1+ progenitors are specified within 24 hr from
foregut patterned endoderm with the combination of
NOGGIN, RA, and FGF10. Hedgehog signaling does notrs
GCG INS GCG INS
SST SST INSINS
PP INS PP INS
GCGCK19 CK19 GCG
GCGTRYP TRYP GCG
NKX6-1 INS NKX6-1 INS Figure 4. NKX6-1 Cells Generated Using
NOGGIN, EGF, and Nicotinamide Have
the Potential to Generate Islet-like
Structures
Immunohistochemical analysis of NKX6-1,
INS, GCG, SST, PP, CK19, and TRYP ex-
pression in the graft recovered from the
mammary fat pad at 6 months post-trans-
plantation of H1 d13 differentiated cells.
Scale bar, 200 mm. See also Figures S4
and S5.appear to play a role in this specification step. The genera-
tion of NKX6-1+ progenitors from this pancreatic endo-
derm is dependent on EGF and nicotinamide signaling
(Figure 5). In contrast, specification of the polyhormonal
program requires 72–96 hr of treatment with stage 3 factors
and is dependent on inhibition of the hedgehog pathway.
Expansion of the derivative lineages is not dependent on
the additionof exogenous EGFandnicotinamide (Figure 5).
By exploiting these differences, it is now possible to design
differentiation strategies that selectively promote the gen-Stemeration of populations of NKX6-1+ progenitors, with mini-
mal contamination of the polyhormonal lineage.
Immunohistochemical analyses of fetal pancreata re-
vealed that the very first hormone+ cells to arise in the hu-
man are insulin+ monohormonal cells (G7.5w). Their
development is followed by the emergence of other mono-
hormonal cells and a small population of polyhormonal
cells (G8w–G9w). These observations suggest that human
pancreatic development lacks the two waves of endocrine
commitment found in the mouse (Jennings et al., 2013).Cell Reports j Vol. 4 j 591–604 j April 14, 2015 j ª2015 The Authors 599
Figure 5. Model of Pancreatic Specifica-
tion from hPSCs
hPSCs can be efficiently differentiated
into definitive endoderm, which can be
patterned to a posterior-foregut-like popu-
lation that has the potential to upregulate
PDX1 expression upon treatment with RA
and FGF10, and inhibition of SHH (using
Sant-1 or cyclopamine) and BMP (using
NOGGIN). PDX1-expressing cells have the
potential to generate two distinct pancre-
atic lineages: (1) a multi-potent pancreatic
progenitor expressing NKX6-1 with the po-
tential to give rise to adult-like mono-
hormonal cells, and (2) a polyhormonal
population that lacks expression of NKX6-1
and the ability to generate functional beta
cells, but generates glucagon+ cells (Basford et al., 2012). Our findings in this study uncover important differences in the regulation of the
two programs and show that the monohormonal cell progenitor is specified within 24 hr by treatment with a combination of stage 3
agonists and the antagonists RA, FGF10, and NOGGIN, independently of hedgehog signaling, and that the generation of the NKX6-1+
progenitor population from this specified pancreatic endoderm is dependent on EGF and nicotinamide signaling. In contrast, specification
of the polyhormonal program requires 72–96 hr of treatment with RA, FGF10, and NOGGIN. Crucially, hedgehog inhibition and expansion of
the derivative lineages are not dependent on the addition of exogenous EGF and nicotinamide.It has been speculated that the absence of an early first-
transition endocrine population in humans is due to the
lack of direct contact of the developing pancreatic bud
with the notochord (Jennings et al., 2013). In the mouse,
expression of Pdx1 is induced by E8.5, when the endoderm
is in contact with the notochord, whereas in humans it is
first expressed when the gut tube has been separated
from the notochord by the dorsal aorta. Given that the
notochord is a known source of hedgehog inhibitors, these
observations suggest that the duration of hedgehog inhibi-
tionmay play a role in the development of the polyhormo-
nal population in vivo. Our findings are consistent with
this hypothesis and clearly demonstrate that the extended
induction period with stage 3 media containing a hedge-
hog inhibitor promotes the development of polyhormonal
cells.
Our observation that EGF signaling is required for the
generation of the equivalent of second-transition progeni-
tors in hPSC differentiation cultures is in line with findings
from targeting studies in the mouse that showed that EgfR/
ErbB1/ and ErbB3/ deficient animals display impaired
branching and islet morphogenesis, and delayed beta cell
differentiation (Erickson et al., 1997; Miettinen et al.,
2000). Although our findings suggest an absolute depen-
dency on EGF signaling, EgfR-deficient animals develop
beta cells, possibly due to functional redundancy of the
other EgfRs expressed in the pancreatic epithelium and
mesenchyme. Two previous studies have reported on the
sequential addition of EGF and nicotinamide to hPSC-
derived pancreatic differentiation cultures (Jiang et al.,600 Stem Cell Reports j Vol. 4 j 591–604 j April 14, 2015 j ª2015 The Autho2007; Zhang et al., 2009). Although increased levels of
NKX6-1 expression were observed over a period of time
in these populations, it is unclear whether these changes
were due to the addition of EGF and nicotinamide, as no
comparisons were made with populations generated
without these factors. As we found that the sequential addi-
tion of these factors is not effective for inducing NKX6-1+
progenitors (data not shown), it is quite possible that the
observed increase in NKX6-1 expression in these studies
was not due to signaling through these pathways.
NKX6-1+ progenitors can develop in hPSC differentiation
cultures without the addition of EGF and nicotinamide
(Kelly et al., 2011; Kroon et al., 2008). However, under
these conditions, the efficient development of these pro-
genitors is hPSC-line dependent. The combination of exog-
enous EGF and nicotinamide signaling largely eliminates
this cell line bias and promotes the generation of
NKX6-1+ progenitors from all of the hPSC lines that
we tested, providing a differentiation platform that can
be widely used.
The binding of EGF ligands to the corresponding recep-
tors induces homo- or heterodimerization with the struc-
turally related family of ErbB homologs, resulting in activa-
tion of the MAPK, Src, PI3-kinase, and PKC signaling
pathways (Citri and Yarden, 2006). PKC may be one inter-
mediate that is responsible for inducing NKX6-1 progeni-
tors following activation of the EGF/EgfR pathway, as Reza-
nia et al. (2012, 2013) demonstrated that TPB and PdBU
(both PKC activators) can induce these progenitors. Addi-
tionally, we found that addition of the PKC inhibitorrs
Go¨6976 (Chen et al., 2009) in the presence of EGF and
nicotinamide resulted in a modest reduction in the per-
centage of NKX6-1+ cells. Further studies will be required
to determine whether other pathways are also involved
in the EGF/EgfR-induced effect, given that the addition of
the PKC inhibitor resulted in only a 10% reduction in pro-
genitor frequency. Under our conditions, the combination
of TPB or PdBU and Noggin led to the induction of only a
small NKX6-1+ population in the absence of EGF and nico-
tinamide.We found that PdBUwasmore effective than TPB
for generating NKX6-1-expressing cells. The reason for the
discrepancy between our findings and those of Rezania
et al. (2012) is currently not known, but it could stem
from differences in the methods used to grow and differen-
tiate the hESCs. In recent studies, both Rezania et al. (2014)
and Pagliuca et al. (2014) initiated TPB or PdBU treatment
at stage 3 rather than stage 4, as described in the original
protocol (Rezania et al., 2012). It is possible that earlier
treatment with these molecules induces the NKX6-1+ pro-
genitor population more efficiently.
Conclusions
In conclusion, we have identified key signaling pathways
that regulate the development of polyhormonal cells and
NKX6-1+ progenitors fromhPSCs.With these new insights,
we are now able to establish differentiation protocols that
selectively induce either one of these populations, enabling
studies focused on elucidating the pathways that regulate
their proliferation and maturation in vitro. The ability to
efficiently generate NKX6-1+ monohormonal progenitors
from many different hPSC lines will provide a platform
for modeling pancreatic development and pathobiology
in vitro, as well as for developing scalable technologies
for future cell-based therapy for the treatment of diabetes.EXPERIMENTAL PROCEDURES
hPSC Culture and Differentiation
H1 andH9 hESC lines were obtained fromWiCell; Mel-1, INSGFP/w,
and NKX6-1GFP/w were provided by Drs. E. Stanley and A. Elefanty
(Micallef et al., 2012); hiPSC 38-2 and MSC-iPSC1 were provided
by Drs. H. Park and G. Daley (Nostro et al., 2011); and BJ-iPSC1
was provided by Drs. T. Araki and B. Neel (Witty et al., 2014). Un-
differentiated cells were maintained as previously described (Ken-
nedy et al., 2007). Differentiation was started when hESCs and
hiPSCs reached 80% confluence. Briefly, after removal of hESCme-
dia, cultures were treated with RPMI media containing 100 ng/ml
of hActivin A and 25 ng/ml mWnt3a for 1 day (d0–d1). mWnt3a
can be substituted by 2 mMCHIR 99021 (Tocris). Cells were treated
with RPMI containing 100 ng/ml of hActivin A and 5 ng/ml hbFGF
for 2 days (d1–d3). At day 3 of differentiation, cultures were treated
with stage 2 media consisting of serum-free differentiation (SFD)
media (Gouon-Evans et al., 2006) containing 50 ng/ml of
hFGF10, in combination with 3 ng/ml mWnt3a and 0.75 mM dor-Stemsomorphin (Sigma). Dorsomorphin was not required for MEL-1
differentiation. NOGGIN (50 ng/ml) could be used to replace dor-
somorphin during stage 2 of differentiation. At d6 of differentia-
tion, themediumwas changed toDMEMwith 1%vol/vol B27 sup-
plement (without vitamin A) (Life Technologies), ascorbic acid
(50 mg/ml; Sigma), KAAD-cyclopamine (0.25 mM; Toronto Research
Chemical), all-trans RA (2 mM; Sigma), hNOGGIN (50 ng/ml), and
hFGF10 (50 ng/ml) for 1–4 days, with the medium changed every
day. SANT-1 (0.25 mM; Tocris) could be used to replace KAAD-cy-
clopamine. At d7–d10, the medium was changed to DMEM with
1% vol/vol B27 supplement (Life Technologies), ascorbic acid
(50 mg/ml; Sigma), hNOGGIN (50 ng/ml), hEGF (50–100 ng/ml),
nicotinamide (10 mM; Sigma) with or without SB (6 mM; Sigma),
and hActivin A at the indicated concentrations. TPB was used at
50 and 500 nM (Calbiochem), and PdBU was used at 10, 30, and
100 nM (Tocris). All cytokines were purchased from R&D Systems
unless otherwise stated. Cultures were maintained in a 5% CO2,
5% O2, 90% N2 environment. At the indicated time points, cells
were harvested and analyzed by real-time qPCR, immunocyto-
chemistry, and flow cytometry, or harvested for transplantation.
Flow Cytometry
Monolayer cultures generated from hPSC differentiation experi-
ments were dissociated by incubation with trypsin (0.25%
trypsin-EDTA) and the cells were stained for the presence of
the appropriate markers. NKX6-1GFP/w was analyzed for GFP
expression by flow cytometry without fixation. Day 7–17 cells
were stained for NKX6-1 (1:2,000; F55A10-c, developed by
Dr. Ole Madson and distributed by the Developmental Studies Hy-
bridoma Bank [DSHB]), C-peptide (1:300; GN-ID4-c, developed by
Dr. Ole Madson and distributed by the DSHB), and anti-mouse
immunoglobulin G (IgG)-phycoerythrin, IgG-Alexa 488, and
anti-rat IgG-APC (Jackson ImmunoResearch). Mouse IgG (Jackson
ImmunoResearch) and rat IgG (Santa-Cruz Biotechnologies) were
used for isotype controls. Intracellular protein staining was carried
out on cells fixedwith 4%paraformaldehyde (ElectronMicroscopy
Sciences) in PBS. Staining was performed in PBS with 4% fetal calf
serum and 0.5% saponin (Sigma). Stained cells were analyzed on
an LSRII flow cytometer (BD). Data were analyzed using FlowJo
software (Treestar).
Immunostaining
Immunostaining of monolayer cultures was performed as previ-
ously described (Nostro et al., 2011). The following primary anti-
bodies were used: goat anti-PDX1 (1:10,000; a gift from Dr. Chris
Wright), NKX6-1 (1:2,000; F55A10-c; DSHB), and SOX9 (1:400;
Millipore). The stained cells were visualized using a digital inverted
fluorescence microscope (AMG EVOS).
Animal Experiments
All animal experiments were approved by the University Health
Network Animal Research Committee. Approximately 5–10
million H1-derived d13 cells were mechanically dislodged and re-
suspended in 20–40 ml Matrigel (BD) and then transplanted into
the mammary fat pad of NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)
mice as previously described (Stewart et al., 2011). Grafts were har-
vested at 1.5, 3, 5, and 6 months post-transplantation. For kidneyCell Reports j Vol. 4 j 591–604 j April 14, 2015 j ª2015 The Authors 601
capsule transplantation, approximately 5–10 million H1-derived
d13 cells from five different experiments were transplanted into
the kidney capsules. Five mice were transplanted per experiment,
fora totalof25mice.Theculturedcellsweremechanicallydislodged
and resuspended in 1.5ml ofNENA in 1.5mlmicrocentrifuge tubes
and shipped overnight at room temperature to the University of
Massachusetts Medical School for subrenal transplantation. All an-
imal use was in accordance with the guidelines of the Animal Care
and Use Committee of the University of Massachusetts Medical
School, and conformed to the recommendations in the Guide for
the Care and Use of Laboratory Animals (Institute of Laboratory Ani-
mal Resources, National Research Council, National Academy of
Sciences, 1996). Briefly, the mice were anesthetized and prepared
for surgery. The skin and muscle layer over the spleen were incised
and the kidney was gently externalized with forceps. H1-derived
pancreatic cells (suspended in CMRL plus 1% FBS) were injected
into the subrenal capsular space using a Surflo winged infusion set
(23 g 3 3/4 inch; Terumo Medical). The kidney was then replaced
in the abdominal cavity, the muscle was sutured, and the skin was
closed with an Autoclip wound closure system (Fisher Scientific).Glucose-Induced C-Peptide Secretion
Mice were fasted overnight and blood was collected following
intraperitoneal injection of glucose (2.0 g/kg body weight). Hepa-
rinized blood was collected with protease inhibitor (aprotinin;
Sigma) at 6, 12, and 18 weeks post-transplantation. Plasma was
stored at80C until it was analyzed for C-peptide by human-spe-
cific ELISAs (ALPCO Diagnostics).Immunohistochemistry
hESC-derived grafts were harvested and fixed in 10% buffered
formalin, embedded in paraffin, and cut into 3 mm sections by
the Pathology Research Program Laboratory at Toronto General
Hospital. For immunohistochemistry, sections were dewaxed in
xylene and transferred to absolute alcohol. The sections were
then rehydrated through a graded series of alcohols prior tomicro-
wave-based antigen retrieval. The sections were incubated in pre-
block solution (10%, serum in PBS). Normal donkey, rabbit, and
goat serums (Jackson ImmunoResearch) were used. Incubation
with primary antibodies (diluted in PBS, 0.3% Triton X, 0.3%
BSA) was performed overnight at 4C in a humidified chamber.
The following primary antibodies were used: C-peptide (DSHB,
1:1,000), insulin (Dako, 1:1,000), somatostatin (Beta Cell Biology
Consortium, 1:500), pancreatic polypeptide (Peninsula Labora-
tories, 1:500), glucagon (Sigma, 1:500), cytokeratin 19 (Abcam,
1:800), nkx6-1 (DSHB, 1:2,000), and trypsin (R&D, 1:300). Sec-
tions were washed with PBS-Tween and then incubated with fluo-
rescence-conjugated secondary antibody for 45 min at room tem-
perature. The following secondary antibodies were used: anti-rat
IgG-Cy3 (Jackson ImmunoResearch), anti-mouse IgG-DyLight
594 (Thermo Scientific), anti-guinea pig IgG-Alexa 488 (Jackson
ImmunoResearch), anti-mouse IgG-DyLight 488 (Thermo Scienti-
fic), anti-mouse IgG-Alexa 488 (Jackson ImmunoResearch), anti-
sheep IgG-Alexa 647 (Life Technologies), and anti-mouse IgG-
Alexa 647 (Life Technologies). Slides were counterstained with
DAPI (Biotium) prior to mounting with fluorescence mounting
medium (DAKO).602 Stem Cell Reports j Vol. 4 j 591–604 j April 14, 2015 j ª2015 The AuthoReal-Time qPCR
Total RNA was prepared with the RNAqueous-Micro Kit (Ambion)
and treated with RNase-free DNase (Ambion). Then, 500 ng to 1 mg
of RNAwas reverse transcribed into cDNA using randomhexamers
and Oligo (dT) with Superscript III Reverse Transcriptase (Invitro-
gen). Real-timeqPCRwas performed on aMasterCycler EP RealPlex
(Eppendorf) using the QuantiFast SYBR Green PCR Kit (QIAGEN).
The oligonucleotide sequences are available on request. A 10-fold
dilution series of sonicated mouse or human genomic DNA stan-
dards ranging from 50 ng/ml to 5 pg/ml was used to evaluate the
efficiency of the PCR and calculate the copy number of each
gene relative to the housekeeping gene TBP.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.02.017.
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